Excipient-Free Inhalable Microparticles of Azithromycin Produced by Electrospray: A Novel Approach to Direct Pulmonary Delivery of Antibiotics.
azithromycin
dry powder
electrospray
microparticles
pulmonary administration
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
20
10
2021
revised:
08
11
2021
accepted:
16
11
2021
entrez:
28
12
2021
pubmed:
29
12
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Inhalation therapy offers several advantages in respiratory disease treatment. Azithromycin is a macrolide antibiotic with poor solubility and bioavailability but with a high potential to be used to fight lung infections. The main objective of this study was to generate a new inhalable dry powder azithromycin formulation. To this end, an electrospray was used, yielding a particle size around 2.5 µm, which is considered suitable to achieve total deposition in the respiratory system. The physicochemical properties and morphology of the obtained microparticles were analysed with a battery of characterization techniques. In vitro deposition assays were evaluated after aerosolization of the powder at constant flow rate (100 L/min) and the consideration of the simulation of two different realistic breathing profiles (healthy and chronic obstructive pulmonary disease (COPD) patients) into a next generation impactor (NGI). The formulation was effective in vitro against two types of bacteria,
Identifiants
pubmed: 34959270
pii: pharmaceutics13121988
doi: 10.3390/pharmaceutics13121988
pmc: PMC8704604
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Pharm Sci. 2010 Jun 14;40(3):239-47
pubmed: 20371286
Int J Pharm. 2020 Dec 15;591:119970
pubmed: 33059013
Front Pharmacol. 2018 Jul 10;9:740
pubmed: 30042679
Int J Pharm. 2020 Sep 25;587:119711
pubmed: 32739389
Pharmacol Ther. 2014 Aug;143(2):225-45
pubmed: 24631273
Biomaterials. 2018 Apr;160:107-123
pubmed: 29407340
Antimicrob Agents Chemother. 1998 Feb;42(2):414-8
pubmed: 9527796
J Aerosol Sci. 2018 Nov;125:164-181
pubmed: 30662086
Front Microbiol. 2021 Mar 16;12:642541
pubmed: 33796090
Int J Mol Sci. 2017 May 16;18(5):
pubmed: 28509852
Adv Drug Deliv Rev. 2016 May 1;100:102-15
pubmed: 26780404
J Aerosol Med Pulm Drug Deliv. 2016 Apr;29(2):196-206
pubmed: 26447531
Sens Actuators B Chem. 2020 Jun 1;312:
pubmed: 32606491
Antimicrob Agents Chemother. 2005 Apr;49(4):1377-80
pubmed: 15793115
AAPS PharmSciTech. 2014 Dec;15(6):1574-87
pubmed: 25139763
Pharm Res. 2018 Jan 08;35(2):28
pubmed: 29374368
Eur J Med Chem. 2020 Dec 1;207:112739
pubmed: 32871342
Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163
pubmed: 32853038
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110070
pubmed: 31546372
Int J Pharm. 2008 Aug 6;360(1-2):1-11
pubmed: 18583072
Eur J Pharm Sci. 2014 Feb 14;52:191-205
pubmed: 24215736
Adv Drug Deliv Rev. 2014 Aug;75:32-52
pubmed: 24735676
Int J Infect Dis. 2021 Jun;107:69-71
pubmed: 33878463
Pharmaceutics. 2020 Sep 23;12(10):
pubmed: 32977672
J Inflamm Res. 2015 Jan 22;8:29-47
pubmed: 25653549
Front Microbiol. 2014 Apr 22;5:178
pubmed: 24795709
Int J Pharm. 2019 Apr 20;561:102-113
pubmed: 30797863
Int J Pharm. 2010 Aug 16;395(1-2):205-14
pubmed: 20595022
Int J Pharm. 2020 Sep 25;587:119684
pubmed: 32736016
Int J Pharm. 2021 Feb 1;594:120165
pubmed: 33309835
Int J Chron Obstruct Pulmon Dis. 2011;6:353-63
pubmed: 21760722